Neumora's NMRA-511 Shows 'Best-in-Class' Potential in Alzheimer's Agitation; Key Phase 3 Readout Expected Q2
NMRA has more than doubled off its 52-week low of $0.611.
Summary
Neumora Therapeutics reported positive fourth quarter and full year 2025 financial results, highlighting a strong cash position of $182.5 million, extending its operational runway into Q3 2027. The company also provided significant pipeline updates, including new Phase 1b data for NMRA-511 in Alzheimer's disease agitation, which demonstrated effect sizes supporting a potential 'best-in-class' profile. Additionally, the KOASTAL-2 and -3 studies for navacaprant were fully enrolled in Q1 2026, with a joint topline data readout anticipated in the second quarter of 2026. NMRA-898 was also selected as the lead program in the M4 franchise for schizophrenia, based on promising Phase 1 clinical results. These updates provide multiple positive catalysts and de-risk the pipeline for this clinical-stage biotech, with the upcoming Phase 3 data for navacaprant being a major near-term value driver. Investors will be closely watching the KOASTAL-2 and -3 data in Q2 2026, as well as further data for NMRA-511 and NMRA-898 in the second half of 2026.
At the time of this announcement, NMRA was trading at $2.33 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $389.3M. The 52-week trading range was $0.61 to $3.65. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.